EVGN חוב כולל להון Evogene Ltd

Evogene Ltd. (EVGN) is implementing environmental standards in biomedicine, reducing laboratory waste through digital modeling. The company's revenues are based on the sale of genomic analysis licenses for the development of pharmaceuticals and agricultural products. This chart demonstrates a total debt-to-equity ratio of 0.00. High confidence from global partners confirms the company's status as a leading developer of intelligent search systems.

Professional selection of resilient assets begins with an analysis of financial leverage, where low debt loads minimize default risk. This debt-to-equity ratio measures the proportion of total liabilities within the capital structure, which for Evogene Ltd. (EVGN) confirms the ability to fund the development of AI platforms and clinical trials through equity and partner milestone payments.